Call us : USA : 1-631-381-2994; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs Bispecific Antibody Blog

Menu

Skip to content
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News

Bispecific Antibody Development Services

Creative Biolabs offers several technical platforms and bispecific antibody (BsAb) formats for customers and focus on ideal BsAbs design and development that meet all requirements of the customers.

Read More

Customized Bispecific Antibody Products

Creative Biolabs collects hot therapeutic targets and provides a variety of customized bispecific antibody (BsAb) products including Tandem scFv, Tandem Fab, Diabody, IgG-scFv, CrossMab, IgG-IgG, Triple Body, Fab-IgG, TandAb, Single-chain Diabody, and Single-chain Triplebody

Read More

Bispecific Antibody Applications

Creative Biolabs offers a variety of bispecific antibodies (BsAbs) for different applications: oncology, immunology, hematology, ophthalmology, osteology, pulmonary and respiratory diseases, pretargeting systems, diagnostics, and gene therapy.

Read More

Bispecific Antibody Developability Assessment

Creative Biolabs has established a mature platform for bispecific antibody (BsAb) developability assessment, which consist of a suite of in silico tools, protein structure expertise, and experimental protocols.

Read More

Bispecific Antibodies Targeting Dual Tumor-associated Antigens

December 24, 2020Bispecific Antibody ResearchBispecific Antibody, bsAb, Tumor-associated Antigenbiobsab

In the past two decades, advances in biotechnology have brought improvements in protein engineering and manufacturing technology, and promoted the development of increasingly complex bispecific antibodies (BsAbs). At present, more than 100Read More…

Difficulties and Prospects in the Research and Development of Bispecific Antibodies

October 16, 2020Bispecific Antibody Clinic, Bispecific Antibody ResearchBispecific Antibody, Bispecific Antibody Development, bsAbbiobsab

Nowadays, in the tide of research and development of biological agents, antibody drugs are in an explosive period. The major monoclonal antibody (McAb) drugs have accounted for more than half of theRead More…

Current Status of Research and Development of Multispecific Antibodies

October 16, 2020Bispecific Antibody Clinic, Bispecific Antibody ResearchBispecific Antibody, bsAb, Multispecific Antibodiesbiobsab

Antibody drug research and development has shown explosive growth in the past decade. A total of 31 antibody drugs and 10 antibody biosimilar drugs were approved on the global market from 2013Read More…

How to Develop A Qualified Bispecific Antibody

August 6, 2020Bispecific Antibody Clinic, Bispecific Antibody ResearchBispecific Antibody Development, bsAbbiobsab

In 1960, Nisonoff and his collaborators at the Roswell Park Memorial Institute in New York first proposed the original concept of bispecific antibodies (BsAbs). Since then, with the great progress in theRead More…

Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia

June 27, 2019Bispecific Antibody Clinic, NewsALL, Bispecific T Cell Engager, BiTE, BLINCYTObiobsab

Recently, Amgen announced the long-term efficacy of the company’s bispecific antibody Blincyto (blinatumomab) in the treatment of patients with acute lymphoblastic leukemia (ALL) at the European Hematology Association (EHA) conference. The medianRead More…

Recent Advances in Hot Areas of Bispecific Antibodies Such as PARP Inhibitors

April 17, 2019Bispecific Antibody ResearchBispecific Antibody, PARPbiobsab

In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by the U.S. Food and Drug Administration (FDA), becoming the first targeted therapy for patients with neurotrophic receptor tyrosine kinase (NTRK)Read More…

TG Therapeutics’s new anti-CD47 and CD19 therapy TG-1801 enters Phase I clinical practice

March 2, 2019Bispecific Antibody Clinic, Bispecific Antibody Research, NewsbsAb, CD19-CD47biobsab

TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…

The World’s First Single-domain Antibody Drug Cablivi is Approved by FDA in the United States

February 19, 2019NewsaTTP, sdAb, Single-domain Antibodybiobsab

French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the single-domain antibody (sdAb) drug Cablivi (caplacizumab) combined with plasma exchange and immunosuppressive therapy, for theRead More…

Regeneron’s Lymphoma Bispecific Antibody Drug Achieved 100% Overall Response Rate

December 20, 2018Bispecific Antibody ResearchCD20, CD3, REGN1979biobsab

In the 2018 American Society of Hematology (ASH) annual meeting, Regeneron, the US biopharmaceutical company, announced new data from Phase I proof-of-concept studies on the bispecific antibody REGN1979 for the treatment ofRead More…

Research and Development of Blinatumomab in B Cell Malignant Tumor

November 22, 2018Bispecific Antibody Clinic, Bispecific Antibody ResearchBispecific Antibody, Bispecific T Cell Engager, Blinatumomabbiobsab

Blinatumomab is a CD19/CD3 bispecific antibody that is the first bispecific T cell engager (BiTE) and the first CD19-specific antibody approved by the U.S. Food and Drug Administration (FDA). As an immunotherapyRead More…

Posts navigation

  • 1
  • 2
  • Next »

Categories

  • Bispecific Antibody Clinic
  • Bispecific Antibody Research
  • News

Recent Posts

  • Bispecific Antibodies Targeting Dual Tumor-associated Antigens
  • Difficulties and Prospects in the Research and Development of Bispecific Antibodies
  • Current Status of Research and Development of Multispecific Antibodies
  • How to Develop A Qualified Bispecific Antibody
  • Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia

Archives

  • December 2020
  • October 2020
  • August 2020
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018

Contact Us

USA:
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: info@creative-biolabs.com
Europe:
Tel: 44-207-097-1828
Copyright © Creative Biolabs Bispecific Antibody Blog
Powered by WordPress , Designed and Developed by templatesnext
MENU
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News